NOVN Stock Price - Novan Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN)

Dec. 29, 2017 at 10:50 p.m. ET
on BusinessWire - BZX

The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)

Dec. 29, 2017 at 1:46 p.m. ET
on ACCESSWIRE

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018

Dec. 28, 2017 at 10:47 a.m. ET
on ACCESSWIRE

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN

Dec. 27, 2017 at 7:52 p.m. ET
on ACCESSWIRE

SHAREHOLDER ALERT:Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVN

Dec. 23, 2017 at 8:00 a.m. ET
on BusinessWire - BZX

NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN)

Dec. 22, 2017 at 10:51 p.m. ET
on GlobeNewswire

The Klein Law Firm Reminds Investors of a Class Action on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)

Dec. 21, 2017 at 10:44 a.m. ET
on ACCESSWIRE

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Novan, Inc. Investors and Encourages Investors to Contact the Firm (NOVN)

Dec. 20, 2017 at 9:47 p.m. ET
on BusinessWire - BZX

Cohen Milstein Sellers & Toll PLLC Announces Investigation of Novan Inc.

Dec. 20, 2017 at 4:10 p.m. ET
on BusinessWire - BZX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline - NOVN

Dec. 20, 2017 at 3:31 p.m. ET
on ACCESSWIRE

Novan, Inc. is a late-stage pharmaceutical company, which focuses on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the it's nitric oxide platform. The company has two key components of nitric oxide platform: Proprietary Nitricil Technology and Topical Formulation Science. Its Proprietary Nitricil Technology drives the creation of new chemical entities. The Topical Formulation Science use to modulate or tune product candidates for specific indications. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC. (See Full Profile)

Name	Chg %	Market Cap
Omeros Corp.	-12.88%	$680.35M
Ono Pharmaceutical Co. Ltd. ADR	-2.29%	$16.83B
Onconova Therapeutics Inc.	0.77%	$17.67M
Oncolix Inc.	0.53%	$3.95M

Competitor Data Provided By

Dow	24,202.60	669.40	2.84%
S&P 500	2,658.55	70.29	2.72%
Nasdaq	7,220.54	227.88	3.26%
GlobalDow	3,037.24	11.01	0.36%
Gold	1,358.80	-2.10	-0.15%
Oil	65.69	0.14	0.21%

Novan Inc.

$ 3.09

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Novan's stock rockets 58% premarket after positive trial results for skin treatment

Novan says statistical significance differed among two late-stage trials for acne drug

Novan stock halted on results of two late-stage acne drug trials

Novan started at outperform with $27 stock price target at Wedbush Securities

Stocks

Columns

Authors

Topics

^$ 3.09